C
Cleveland HeartLab
Clinical laboratory and disease management firm, develops biomarker technologies and diagnostic tests
About Cleveland HeartLab
Cleveland HeartLab operates as a clinical reference laboratory with a specialized focus on the prevention, diagnosis, and management of cardiovascular disease. The firm was established in 2009 as a spin-off from the Cleveland Clinic by co-founders Jake Orville and Dr. Marc Penn. Dr. Penn, a cardiologist and researcher, brought deep scientific expertise in cardiovascular diagnostics, while Orville provided extensive experience in the diagnostic and medical technology industries. Their collaboration aimed to commercialize novel biomarker technologies to address gaps in traditional cardiovascular risk assessment.
The company's business is centered on providing advanced biomarker testing services to clinicians, hospitals, and corporate wellness programs. It generates revenue by performing these specialized tests, which go beyond standard cholesterol panels to identify hidden risks for heart disease. The laboratory is both CAP-accredited and CLIA-certified. A key milestone was the acquisition by Quest Diagnostics in December 2017, which integrated Cleveland HeartLab as its national Cardiometabolic Center of Excellence. This strategic move expanded the availability of its specialized tests through Quest's extensive network.
Cleveland HeartLab's core service involves a suite of proprietary diagnostic tests focused on inflammation, genetics, and metabolic markers, which are often overlooked in routine screenings. Its testing portfolio is based on scientific research, with some technologies licensed exclusively, such as a test for Trimethylamine-N-oxide (TMAO), a gut-produced biomarker linked to heart disease risk. The company emphasizes a multi-marker approach, combining several inflammation and biomarker tests to create a more comprehensive risk profile for patients. This allows for personalized interventions aimed at reducing the likelihood of cardiovascular events like heart attacks and strokes. The company also committed to educating healthcare providers and patients on advancements in cardiovascular risk identification through various forums and materials.
Source: Dealroom company dataNews
Open roles
Cleveland HeartLab in the Cleveland ecosystem
The Cleveland HeartLab office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Glengary Ventures
Zapis Capital Group- SLSecond Generation LTD
- HVHealthCare Ventures
Excel Venture Management
Mutual Capital Partners
Series B and later1 investor entered at this stage
Advantage Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cleveland HeartLab on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cleveland HeartLab on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

